(Alliance News) - Horizon Discovery Group PLC on Tuesday said it has licensed its CHOSOURCE gene-edited platform to biotechnology firm Sanyou Biopharmaceuticals Co Ltd.
CHOSOURCE is a gene-edited Glutamine Synthetase platform. Glutamine Synthetase is an enzyme crucial in metabolising nitrogen.
Sanyou will use the platform for the development of its "pre-clinical antibody drug projects".
"Horizon is committed to supporting innovative organizations of all sizes to empower biotherapeutic production using our expression platform. We are proud to have licensed CHOSOURCE to over 80 organizations, from non-for-profit and early stage startups to clinical stage biotechnology and large pharmaceutical companies, and helped enable at least 8 biotherapeutics expressed in these cells to progress into clinical trials," Horizon Discovery's Global Head Bioproduction Jesus Zurdo said.
Horizon shares were 1.3% lower at 187.03 pence each in London on Tuesday afternoon.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
